Taser International Inc. (NASDAQ:TASR) shares are up over 5.5% today on heavy volume after the company reported strong sales in the fourth-quarter that boosted profits for the stun gun maker.
Despite many controversies regarding its products, Taser has managed to grow profits for four straight quarters. For the fourth-quarter, net income grew to $2.3 million, or 4 cents per share, from $179,126, or breakeven per share, in the year-ago period. Revenue rose 53% to $19.3 million from $12.6 million. Analysts surveyed by Thomson Financial expected 4 cents earnings per share on revenue of $19.2 million.
While the market is happy with the results, Taser is far away from the highs it reached in 2004 when safety concerns over the use of the TASERs and a SEC investigation hit the company The government ordered a two-year study by the Department of Justice (yet to be completed) and Amnesty International called the stun guns inhumane. The SEC also investigated the company's accounting practices back then. The investigation ended in 2005.
The company mentions in the report that courts dismissed seven more suits related to wrongful deaths from TASER use, but just last month yet another Taser controversy about police use of the guns made the headlines. Despite all that, it seems customers keep coming back for more, and for now, that's what matters to investors.
If the company continues its growth without new controversies to shake it or competition to speak of (competition remained weak so far), the stock should continue to do well as law-enforcement agencies domestically and around the world continue to adopt this nonlethal (or as some would prefer, 'less-lethal') gun. And lest we forget the opportunities in the personal market as well.
Last updated: February 12, 2012: 09:22 PM
Hot Stocks
DailyFinance Headlines
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
Benzinga Headlines
- Michigan Consumer Sentiment Index Drops
- Don't Bank on Barclays
- GSV Capital Punished for Expanding Facebook Investment
- Chesapeake Gently Lets Go of Gas
- How to Profit off Addicts
TheFlyOnTheWall.com Headlines
- Milestone Aviation Group signs contract for three S-92 helicopters
- Greek parliament approves austerity bill, Reuters reports
- Xstrata shareholders want Glencore offer above three shares, Telegraph says
- France Telecom pursuing greater interest in Egypt's Mobinil, Bloomberg says
- Arab league to ask U.N. for a peacekeeping force in Syria, WSJ says
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
Walmart's New Health Food Push: Is It Too Hard to Swallow?
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger

